The COVID-19 Pandemic Boosted the Global Plasma Therapy Market Growth

The global plasma therapy market is anticipated to grow at a significant CAGR of 13.1% during the forecast period. The global plasma therapy market is projected to be significantly impacted by the COVID-19 pandemic. In the case of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical companies are focusing on effective and rapid technologies for the rapid diagnosis of COVID-19, as well as developing vaccines and new therapeutics to combat the current situation.  Researchers are concentrating their efforts on plasma-based treatments to see if they may be used to treat the COVID-19 virus. For instance, in April 2020, Kamada Ltd. and Kedrion Biopharma, two biopharmaceutical companies specializing in plasma-derived protein therapeutics, announced a global collaboration to develop, manufacture, and distribute a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for COVID-19 patients.

Browse the full report description “Global Plasma Therapy Market Size, Share & Trends Analysis Report by Type (Leukocyte-Rich Fibrin (L-PRF), Pure Platelet-Rich Fibrin (PRF), Leucocyte-Rich PRP, and Pure PRP), by Application (Orthopedics, Dermatology, Dental, and Others), and by End-User (Hospitals & Clinics and Research Institutions) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/plasma-therapy-market 

The Indian Council of Medical Research (ICMR) sought researchers' participation in a clinical trial of convalescent plasma therapy to treat critically ill COVID-19 patients in April 2020 and floated a protocol for the study. BioAegis Therapeutics began studying its lead product, recombinant human plasma gelsolin treatment (RHU-pGSN), in May 2020, expecting it to be a feasible therapeutic alternative for patients with severe COVID-19 lung injury. Further, Biotest became the first plasma protein company in Germany to create an experimental hyper immunoglobulin preparation against COVID-19 in February 2021.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Production 
• By Category 
• By Packaging

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Arthrex Inc., China Biologic Products Inc., and Johnson and Johnson.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Plasma Therapy Market Report Segment

By Type  

• Leukocyte-Rich Fibrin
• Pure Platelet-Rich Fibrin
• Leukocyte-Rich PRP
• Pure PRP

By Application   

• Orthopedics
• Arthritis
• Chronic Tendinitis
• Bone Repair & Regeneration
• Dermatology
• Androgenic Alopecia
• Plastic Surgery
• Dental
• Others (Nerve Injury)

By End-User 

• Hospitals and Clinics
• Research Institute 

Global Plasma Therapy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/plasma-therapy-market